Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 123

Sort by

Sort Order Select

Journal Articles

A Multicenter Randomized Non-Inferiority Study of Homoharringtonine Versus Etoposide in Induction Phase for Chinese Childhood Acute Myeloid Leukemia - a Report from China Children's Leukemia Group (CCLG)

Blood (2019) 134 (Supplement_1): 1356.

https://doi.org/10.1182/blood-2019-127932

Published: 2019

Journal Articles

Single Cell Sequencing Reveals Evolution of Tumor Heterogeneity of Acute Myeloid Leukemia on Quizartinib

Cheryl A Cohler Peretz, MD, Lisa H F McGary, Tanya F Kumar, J Hunter Jackson, Jose Jacob, Robert Durruthy-Durruthy, PhD, Chunxiao Zhang, Mark J. Levis, MD, Alexander E. Perl, MD, Anskar Yu Hung Leung, MD PhD, Catherine C. Smith, MD

Blood (2019) 134 (Supplement_1): 1440.

https://doi.org/10.1182/blood-2019-132105

Published: 2019

Journal Articles

High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma

David G. Coffey, MD, Andrew J. Cowan, MD, Timothy S Martins, PhD, Damian J. Green, MD, Edward N. Libby, III, MD, Rebecca W. Silbermann, MD, Sylvia Chien, Jin Dai, PhD, Alicia Morales, Niall Curley, Bret Gary Degraaff, BS, Ted A Gooley, PhD, Edus H. Warren, MD PhD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 1885.

https://doi.org/10.1182/blood-2019-125383

Published: 2019

Journal Articles

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Maria R Vazquez, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Susan O'Brien, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Jorge E. Cortes, MD, Tapan M. Kadia, MD, William G. Wierda, MD PhD, Guillermo Garcia-Manero, MD, Sara E Dellasala, BS, Kathleen A Kehr, MD, Sherry A. Pierce, BSN, BA, Mary B. Rios, RN, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 2927.

https://doi.org/10.1182/blood-2019-132246

Published: 2019

Journal Articles

Casein Kinase 1 Delta Is a Novel Regulator of mRNA Translation and Druggable Target in Aggressive Lymphomas

Ipsita Pal, PhD, Sohani Das Sharma, PhD, Andre M. Grilo, PhD, Prabhjot S. Mundi, MD, Luigi Scotto, PhD, Abdullah Mahmood Ali, PhD, Luke E Berchowitz, PhD, Siddhartha Mukherjee, MD PhD, Owen O'Connor, MD PhD, Marko Jovanovic, PhD, Changchun Deng, MD PhD

Blood (2019) 134 (Supplement_1): 2864.

https://doi.org/10.1182/blood-2019-129528

Published: 2019

Journal Articles

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Blood (2019) 134 (Supplement_1): 1269.

https://doi.org/10.1182/blood-2019-130996

Published: 2019

Journal Articles

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

Zachary J Walker, BS, MS, Beau M Idler, BA, Michael J VanWyngarden, BS, Brett M. Stevens, PhD, Shelby C Bearrows, BS, Lorraine N Davis, BS, Andrew Hammes, MS, Clayton Smith, MD, Craig T Jordan, PhD, Tomer M Mark, MD MS, Peter A Forsberg, MD, Daniel W Sherbenou, MD PhD

Blood (2019) 134 (Supplement_1): 4404.

https://doi.org/10.1182/blood-2019-121937

Published: 2019

Journal Articles

Combination of Tigecycline and Homoharringtonine Synergistically Enhances Anti-Leukemia and Anti-MDS Effect Followed By Inhibiting Mitochondrial Translation through AKT/Mtorpathway and Downregulation of Anti-Apoptotic Proteins

Jie Jin, MD PhD, Hongyan Tong, Yang Haiyang

Blood (2019) 134 (Supplement_1): 5387.

https://doi.org/10.1182/blood-2019-128171

Published: 2019

Journal Articles

Effectiveness and Survival of 4 Courses of Chemotheray in 321 Children with Acute Myeloid Leukemia in China: A Multicenter, Nonrandomized Clinical Study

Zheng Yong Zhi, MD, Jian Li, MD, Xiaoqin Feng, Mincui Zheng, Chunfu Li, MD, Honggui Xu, Yingyi He, MD& PhD, Huirong Mai, Xiangling He, Lihua Yang, MD PhD, Hong Wen

Blood (2019) 134 (Supplement_1): 2596.

https://doi.org/10.1182/blood-2019-128375

Published: 2019

Journal Articles

A Phase II Single-Arm Open-Labeled Study Evaluating Combination of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) in Newly Diagnosed or Relapsed/Refractory AML Carrying FlT3-ITD

Chunxiao Zhang, Garret MK Leung, MBBS, Sze Pui Tsui, MSc, Ho-Wan Ip, MBBS,FRCPA, Edmond S. K. Ma, MD, Chun Hang Au, PhD, Chris T.L. Chan, PhD, Ka Lam Nelson Ng, PhD, Sze Fai Yip, MD, Bonnie Kho, MD, Harold K K Lee, MD, Qing LIU, Thomas Wing Yan Leung, Yok Lam Kwong, MD FRCP, Anskar Yu Hung Leung, MD PhD

Blood (2019) 134 (Supplement_1): 3825.

https://doi.org/10.1182/blood-2019-126510

Published: 2019

Journal Articles

Comparision of the Clinical and Prognostic Characteristic in Adult and Pediatric AML1/ETO-Positive Acute Myeloid Leukemia

Guopan Yu, Jiaheng Zhou, Jinchan Zhou, Jiale Qiu, Zhao Yin, Changxin Yin, Dan Xu, Xuejie Jiang, MD, Qifa Liu, MD, Fanyi Meng

Blood (2018) 132 (Supplement 1): 5170.

https://doi.org/10.1182/blood-2018-99-116558

Published: 2018

Journal Articles

A Double Priming Induction Regimen for Acute Myeloid Leukemia with Inferior PS Among Resource Limited Areas

Stephen Liang, MD, Siliang Chen, Xiaoli Huang, Zheyuan Qin, Sanbin Wang

Blood (2018) 132 (Supplement 1): 5173.

https://doi.org/10.1182/blood-2018-99-118732

Published: 2018

Journal Articles

A Safety Study of the Addition of Omacetaxine to the Standard-of-Care Induction Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients

Sonia Christian, MD, Kelley E. Kozma, DO, Stephanie Barath, Ardaman Shergill, MD, Damiano Rondelli, MD, David Peace, MD, Santosh L. Saraf, MD, Annie Lee Oh, MD, Karen Sweiss, PharmD, Irum Khan, MBBS, Pritesh Patel, MD, Arkadiusz Dudek, MD PhD, John G. Quigley

Blood (2018) 132 (Supplement 1): 5218.

https://doi.org/10.1182/blood-2018-99-111412

Published: 2018

Journal Articles

AC0010, a Novel BTK Inhibitor, Exerts Anti-Leukemia Effects and Synergizes the Efficiency of Homoharringtonine in AML

Jie Jin, MD PhD, Shujuan Huang

Blood (2018) 132 (Supplement 1): 5153.

https://doi.org/10.1182/blood-2018-99-114350

Published: 2018

Journal Articles

hnRNP K: A Regulator of Global Transcription and Translation That Drives Lymphomagenesis

Blood (2018) 132 (Supplement 1): 1346.

https://doi.org/10.1182/blood-2018-99-116163

Published: 2018

Journal Articles

Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles

Disha Malani, MRes, Ashwini Kumar, MRes, Bhagwan Yadav, PhD, Mika Kontro, MD, Swapnil Potdar, MSc, Samuli Eldfors, MSc, Jani Saarela, Bjørn Tore Gjertsen, Riikka Karjalainen, Tero Aittokallio, Astrid Murumagi, Maija Wolf, PhD, Simon Anders, PhD, Krister Wennerberg, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD

Blood (2017) 130 (Supplement 1): 854.

https://doi.org/10.1182/blood.V130.Suppl_1.854.854

Published: 2017

Journal Articles

Omacetaxine Mepesuccinate for Patients with Higher-Risk MDS and CMML after Failure of Hypomethylating Agents: A Phase II Trial

Nicholas J Short, MD, Guillermo Garcia-Manero, MD, Kiran Naqvi, MDMPH, Steven Kornblau, MD, Koichi Takahashi, MD, Guillermo Montalban-Bravo, MD, Rita Khouri, Michael Andreeff, MD PhD, Marina Konopleva, MD PhD, Courtney D. DiNardo, MDMSc, Yesid Alvarado, MD, Marie Ghosn, Zeev Estrov, MD, Prithviraj Bose, MD, Rubiul Islam, Xiao Dong, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD

Blood (2017) 130 (Supplement 1): 2967.

https://doi.org/10.1182/blood.V130.Suppl_1.2967.2967

Published: 2017

Journal Articles

Combination of Omacetaxine Mepesuccinate (homoharringtonine) and Sorafenib As an Effective Regimen for Acute Myeloid Leukemia (AML) Carrying FLT3-ITD

Garret MK Leung, Chunxiao Zhang, Alan WL To, Stephen SY Lam, Yok Lam Kwong, Anskar Leung, MD PhD

Blood (2017) 130 (Supplement 1): 3849.

https://doi.org/10.1182/blood.V130.Suppl_1.3849.3849

Published: 2017

Journal Articles

The Intermediate Dose Verse Conventional Dose Cytarabine in Induction Therapy in Adult Acute Myeloid Leukemia: A Phase Ⅲ Randomized Controlled Trial

Hui Wei, MD, Ying Wang, MD, Dong Lin, MD, Chunlin Zhou, Bingcheng Liu, MD, Shaowei Qiu, MD, Benfa Gong, Kaiqi Liu, Guangji Zhang, Shuning Wei, Xiaoyuan Gong, Yuntao Liu, Yan Li, MD, Yingchang Mi, MD, Jianxiang Wang, MD

Blood (2017) 130 (Supplement 1): 146.

https://doi.org/10.1182/blood.V130.Suppl_1.146.146

Published: 2017

Journal Articles

MRD Is an Independent Prognostic Factor in Acute Myeloid Leukemia Carrying t(8;21) Chromosomal Abnormalities

Hui Wei, MD PhD, Ying Wang, MD, Dong Lin, MD PhD, Chunlin Zhou, MD PhD, Bingcheng Liu, Shaowei Qiu, Benfa Gong, Guangji Zhang, Kaiqi Liu, Shuning Wei, Xiaoyuan Gong, MD, Yuntao Liu, Yan Li, MD, Runxia Gu, MD PhD, Yingchang Mi, MD PhD, Jianxiang Wang, MD

Blood (2016) 128 (22): 1672.

https://doi.org/10.1182/blood.V128.22.1672.1672

Published: 2016

NARROW

A Multicenter Randomized Non-Inferiority Study of Homoharringtonine Versus Etoposide in Induction Phase for Chinese Childhood Acute Myeloid Leukemia - a Report from China Children's Leukemia Group (CCLG)

Single Cell Sequencing Reveals Evolution of Tumor Heterogeneity of Acute Myeloid Leukemia on Quizartinib

High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Casein Kinase 1 Delta Is a Novel Regulator of mRNA Translation and Druggable Target in Aggressive Lymphomas

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

Combination of Tigecycline and Homoharringtonine Synergistically Enhances Anti-Leukemia and Anti-MDS Effect Followed By Inhibiting Mitochondrial Translation through AKT/Mtorpathway and Downregulation of Anti-Apoptotic Proteins

Effectiveness and Survival of 4 Courses of Chemotheray in 321 Children with Acute Myeloid Leukemia in China: A Multicenter, Nonrandomized Clinical Study

A Phase II Single-Arm Open-Labeled Study Evaluating Combination of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) in Newly Diagnosed or Relapsed/Refractory AML Carrying FlT3-ITD

Comparision of the Clinical and Prognostic Characteristic in Adult and Pediatric AML1/ETO-Positive Acute Myeloid Leukemia

A Double Priming Induction Regimen for Acute Myeloid Leukemia with Inferior PS Among Resource Limited Areas

A Safety Study of the Addition of Omacetaxine to the Standard-of-Care Induction Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients

AC0010, a Novel BTK Inhibitor, Exerts Anti-Leukemia Effects and Synergizes the Efficiency of Homoharringtonine in AML

hnRNP K: A Regulator of Global Transcription and Translation That Drives Lymphomagenesis

Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles

Omacetaxine Mepesuccinate for Patients with Higher-Risk MDS and CMML after Failure of Hypomethylating Agents: A Phase II Trial

Combination of Omacetaxine Mepesuccinate (homoharringtonine) and Sorafenib As an Effective Regimen for Acute Myeloid Leukemia (AML) Carrying FLT3-ITD

The Intermediate Dose Verse Conventional Dose Cytarabine in Induction Therapy in Adult Acute Myeloid Leukemia: A Phase Ⅲ Randomized Controlled Trial

MRD Is an Independent Prognostic Factor in Acute Myeloid Leukemia Carrying t(8;21) Chromosomal Abnormalities

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only